| Efficacy and safety of SKCPT in patients with knee osteoarthritis: A multicenter, randomized, double-blinded, active-controlled phase III clinical trial.J Ethnopharmacol | PMID 39303963无 PMCID | 2025-Jan-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.N Engl J Med | PMID 39555826无 PMCID | 2025-Jan-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.N Engl J Med | PMID 39879593PMC7617355 | 2025-Jan-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Unanchored simulated treatment comparison on survival outcomes using parametric and Royston-Parmar models with application to lenvatinib plus pembrolizumab in renal cell carcinoma.BMC Med Res Methodol入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | PMID 39885377PMC11780865 | 2025-Jan-30 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Comparison of subconjunctival TRIamcinolone acetonide injection and intravitreal dexamethasone (OZurdex) injection for uveitic and postoperative macular oedema: the TRIOZ study.Br J Ophthalmol | PMID 39168590无 PMCID | 2025-Jan-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine Nonresponse: The BEe-HIVe Randomized Clinical Trial.JAMA | PMID 39616603PMC11610526 | 2025-Jan-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Early Improvements With Atogepant for the Preventive Treatment of Migraine: Results From 3 Randomized Phase 3 Trials.Neurology | PMID 39715475PMC11668519 | 2025-Jan-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple Sclerosis.Neurology | PMID 39960455无 PMCID | 2025-Jan-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Treatment of hidradenitis suppurativa with adalimumab in the PIONEER I and II randomized controlled trials reduced indices of systemic inflammation, recognized risk factors for cardiovascular disease.Clin Exp Dermatol | PMID 39141589无 PMCID | 2025-Jan-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial.Vaccine | PMID 39675209无 PMCID | 2025-Jan-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39842010无 PMCID | 2025-Jan-23 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 无 KM 图 |
| Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]).Breast Cancer Res疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:非 KM 图;Fig. 3:森林图/亚组分析图。 | PMID 39849600PMC11761723 | 2025-Jan-23 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| The first multiple center prospective study of rhFSH CTP in patients undergoing assisted reproductive technology in China.Sci Rep | PMID 39837901PMC11751185 | 2025-Jan-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.J Clin Oncol | PMID 39250535PMC11771353 | 2025-Jan-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.J Clin Oncol | PMID 39265124PMC11771365 | 2025-Jan-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors.J Clin Oncol | PMID 39411812PMC11771356 | 2025-Jan-20 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39798578无 PMCID | 2025-Jan-18 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 无 KM 图 |
| Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.Lancet | PMID 39798579PMC12282661 | 2025-Jan-18 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 已完成 |
| A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial.Clin Cancer Res | PMID 39540844PMC11739777 | 2025-Jan-17 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: a secondary analysis of the ESCAPE-TRD randomized clinical trial.CNS Spectr | PMID 39819527PMC13064706 | 2025-Jan-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study.Blood | PMID 39331724PMC11775507 | 2025-Jan-16 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Improving Neck and Jawline Aesthetics With OnabotulinumtoxinA by Minimizing Platysma Muscle Contraction Effects: Efficacy and Safety Results in a Phase 3 Randomized, Placebo-Controlled Study.Aesthet Surg J | PMID 39475141PMC11736717 | 2025-Jan-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39813643无 PMCID | 2025-Jan-16 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Lerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial.Nat Commun疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:森林图/亚组分析图;Fig. 3:森林图/亚组分析图。 | PMID 39820749PMC11739584 | 2025-Jan-16 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Effect of Lemborexant on Daytime Functioning in Adults With Insomnia: Patient-Reported Outcomes From a Phase 3 Clinical Trial.Prim Care Companion CNS Disord | PMID 39823487无 PMCID | 2025-Jan-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term changes in carotid intima-media thickness according to baseline blood pressure level: J-STARS Echo study.J Neurol Sci | PMID 39673820无 PMCID | 2025-Jan-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure.Circulation | PMID 39340828PMC11732259 | 2025-Jan-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer.Signal Transduct Target Ther | PMID 39800716PMC11725569 | 2025-Jan-13 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Echocardiographic phenotypes of diabetic myocardial disorder: evolution over 15 months follow-up in the ARISE-HF trial.Cardiovasc Diabetol | PMID 39806375PMC11730511 | 2025-Jan-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies.J Crohns Colitis | PMID 39804294PMC11772864 | 2025-Jan-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.J Clin Oncol | PMID 39298738PMC11709001 | 2025-Jan-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial.J Clin Oncol | PMID 39303200PMC11709003 | 2025-Jan-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Efficacy and Safety of Roxadustat for Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: A Randomized, Open-Label, Active-Controlled Phase III Study.J Clin Oncol | PMID 39353163PMC11708981 | 2025-Jan-10 | 0.95 | The study is a Phase III randomized trial in oncology patients with a drug intervention and reports original results, but it does not have a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP). The primary endpoint is change in hemoglobin concentration, which is a continuous biomarker, not a time-to-event outcome. | 待处理 |
| Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy.J Clin Oncol | PMID 39353164PMC11708988 | 2025-Jan-10 | 0.95 | The record describes a Phase III randomized trial in oncology (cervical cancer) with original results. However, the intervention is surgical (simple vs. radical hysterectomy), not a drug-containing intervention. The primary and secondary endpoints assessed are sexual health and quality of life (non-time-to-event), not a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). | 待处理 |
| First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial.Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39389055无 PMCID | 2025-Jan-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk.N Engl J Med | PMID 39225259无 PMCID | 2025-Jan-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies.Blood | PMID 39316653PMC11738036 | 2025-Jan-09 | 0.60 | The record is a secondary analysis of two Phase III RCTs with a time-to-event endpoint (EFS). However, the abstract does not establish a drug-containing intervention; it focuses on risk stratification and outcomes of therapy protocols. Without explicit drug vs. non-drug (or standard-of-care) randomized comparison, the drug_intervention criterion cannot be met. | 待处理 |
| Effect of add-on naldemedine treatment in patients with cancer and opioid-induced constipation insufficiently responding to magnesium oxide: a pooled, subgroup analysis of two randomized controlled trials.Jpn J Clin Oncol | PMID 39354673PMC11708229 | 2025-Jan-08 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Patient experience with eosinophilic esophagitis symptoms and impacts on daily life based on in-trial qualitative interviews.J Patient Rep Outcomes | PMID 39777591PMC11711566 | 2025-Jan-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease.Alzheimers Res Ther | PMID 39780249PMC11708093 | 2025-Jan-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Fatigue After Stroke Educational Recovery Program: A Prospective, Phase III, Randomized Controlled Trial.J Am Heart Assoc | PMID 39719403PMC12054429 | 2025-Jan-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Challenges in multinational rare disease clinical studies during COVID-19: regulatory assessment of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease.J Neurol | PMID 39775064PMC11706903 | 2025-Jan-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.Lancet | PMID 39706209无 PMCID | 2025-Jan-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy.J Antimicrob Chemother | PMID 39556192PMC11695908 | 2025-Jan-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial.JNCI Cancer Spectr | PMID 39579142PMC11708780 | 2025-Jan-03 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Abdominal visceral and subcutaneous adipose tissue associations with postmenopausal breast cancer incidence.JNCI Cancer Spectr | PMID 39847539PMC11879126 | 2025-Jan-03 | 0.90 | The study is a randomized Phase III trial with a time-to-event endpoint (breast cancer incidence) but lacks a drug-containing intervention; it evaluates associations of body fat distribution with cancer risk, not a therapeutic intervention. | 待处理 |
| Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.N Engl J Med | PMID 39213194无 PMCID | 2025-Jan-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Asundexian versus Apixaban in Patients with Atrial Fibrillation.N Engl J Med | PMID 39225267无 PMCID | 2025-Jan-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.N Engl J Med | PMID 39282897PMC12080919 | 2025-Jan-02 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 部分完成 |
| Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.N Engl J Med | PMID 39282902PMC11698643 | 2025-Jan-02 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |